OSTEOPOROSIS-MANAGEMENT (DENOSUMAB)

SUMMARY

1. Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody, RANK-ligand inhibitor which works by preventing the development of osteoclasts and reduces bone resorption.

2. Used for the treatment of osteoporosis, drug-induced bone loss, bony metastases, and giant cell tumor of bone.
2. Denosumab is contraindicated in people with low serum calcium levels.

3. The most common side effects are joint and muscle pain in the arms or legs.

5. Given every 6 monthly.

Reference(s)

Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].